Women's values and preferences for thromboprophylaxis during pregnancy: a comparison of direct-choice and decision analysis using patient specific utilities.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 26033397)

Published in Thromb Res on May 22, 2015

Authors

Mark H Eckman1, Pablo Alonso-Coello2, Gordon H Guyatt3, Shanil Ebrahim4, Kari A O Tikkinen5, Luciane Cruz Lopes6, Ignacio Neumann7, Sarah D McDonald8, Yuqing Zhang9, Qi Zhou10, Elie A Akl11, Ann Flem Jacobsen12, Amparo Santamaría13, Joyce Maria Annichino-Bizzacchi14, Wael Bitar15, Per Morten Sandset16, Shannon M Bates17

Author Affiliations

1: Division of General Internal Medicine and Center for Clinical Effectiveness, University of Cincinnati, USA. Electronic address: mark.eckman@uc.edu.
2: Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada; Iberoamerican Cochrane Centre, CIBERESP-IIB Sant Pau, Barcelona, Spain.
3: Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada; Department of Medicine, McMaster University, Hamilton, ON, Canada.
4: Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada; Department of Anaesthesia, McMaster University, Hamilton, ON; Department of Medicine, Stanford University, Stanford; Department of Anaesthesia and Pain Medicine, Hospital for Sick Children, Toronto, ON, Canada.
5: Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada; Departments of Urology and Public Health, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland.
6: Pharmaceutical Sciences, University of Sorocaba, UNISO, Sorocaba, Sao Paolo, Brazil.
7: Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada; Department of Internal Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
8: Departments of Obstetrics & Gynecology, Radiology, and Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada.
9: Division of General Internal Medicine and Center for Clinical Effectiveness, University of Cincinnati, USA.
10: Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada.
11: Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada; Department of Medicine, American University of Beirut, Beirut, Lebanon; Department of Medicine, State University of New York at Buffalo, New York, NY, USA.
12: Department of Obstetrics & Gynecology, Oslo University Hospital and University of Oslo, Oslo, Norway.
13: Unidad de Hemostasia y Trombosis, Hospital de la Vall d'hebron Sant Pau, Barcelona, Spain.
14: Hematology and Hemotherapy Center, Faculty of Medical Sciences, State University of Campinas, Campinas, SP, Brazil.
15: Brooks Memorial Hospital, Dunkirk, NY, USA.
16: Department of Haematology, Oslo University Hospital and University of Oslo, Oslo, Norway.
17: Department of Medicine, McMaster University, Hamilton, ON, Canada; Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada.

Articles cited by this

Measurement of health state utilities for economic appraisal. J Health Econ (1986) 11.70

The long-term clinical course of acute deep venous thrombosis. Ann Intern Med (1996) 6.87

Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet (1996) 6.58

A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med (1999) 5.14

Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.02

VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 4.50

Venous thromboembolic disease and pregnancy. N Engl J Med (2008) 4.00

The clinical course of pulmonary embolism. N Engl J Med (1992) 3.70

The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med (1997) 3.49

Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med (2003) 3.18

Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol (2006) 3.08

Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med (1999) 2.98

Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med (1980) 2.50

Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. Arch Intern Med (1996) 2.50

Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med (2001) 2.37

Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood (2005) 2.07

Recurrent thromboembolism in pregnancy and puerperium. Is there a need for thromboprophylaxis? Am J Obstet Gynecol (1989) 2.06

The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med (1994) 1.96

Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.85

Using alternative statistical formats for presenting risks and risk reductions. Cochrane Database Syst Rev (2011) 1.81

The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med (1997) 1.75

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med (1999) 1.72

Preference-based antithrombotic therapy in atrial fibrillation: implications for clinical decision making. Med Decis Making (2005) 1.68

Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA (1998) 1.67

Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. Thromb Haemost (2007) 1.57

Recurrence of venous thromboembolic disease and use of oral contraceptives. Br Med J (1974) 1.56

Valuing health-related quality of life. A review of health state valuation techniques. Pharmacoeconomics (2000) 1.51

A risk score for the management of pregnant women with increased risk of venous thromboembolism: a multicentre prospective study. Br J Haematol (2009) 1.47

The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br J Haematol (2006) 1.47

Risks of long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Second report of the Sixty Plus Reinfarction Study Research Group. Lancet (1982) 1.41

Incidence, clinical characteristics, and timing of objectively diagnosed venous thromboembolism during pregnancy. Obstet Gynecol (1999) 1.35

Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost (1999) 1.31

Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med (2000) 1.24

Framing of health information messages. Cochrane Database Syst Rev (2011) 1.23

Clarifying values: an updated review. BMC Med Inform Decis Mak (2013) 1.22

Twenty-year clinical experience with the Greenfield filter. Cardiovasc Surg (1995) 1.12

Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost (1989) 0.97

Prevalence of the post-thrombotic syndrome in young women with previous venous thromboembolism. Br J Haematol (2000) 0.95

Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. N Engl J Med (2000) 0.94

Values and preferences in oral anticoagulation in patients with atrial fibrillation, physicians' and patients' perspectives: protocol for a two-phase study. BMC Health Serv Res (2008) 0.91

Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood (2002) 0.90

Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost (2005) 0.90

Thirty-day case-fatality rates for pulmonary embolism in the elderly. Arch Intern Med (1996) 0.90

Application of generalizability theory confirmed lower reliability of the standard gamble than the feeling thermometer. J Clin Epidemiol (2007) 0.87

Methods for measuring temporary health States for cost-utility analyses. Pharmacoeconomics (2009) 0.86

Deep venous thrombosis and pulmonary embolism in pregnancy. Obstet Gynecol Clin North Am (1991) 0.86

Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database Syst Rev (2010) 0.85

Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low-molecular-weight heparin. Am J Obstet Gynecol (2004) 0.83

Pregnancy and venous thromboembolism: 'TIPPS' for risk stratification. Hematology Am Soc Hematol Educ Program (2014) 0.82

Evaluating patient values and preferences for thromboprophylaxis decision making during pregnancy: a study protocol. BMC Pregnancy Childbirth (2012) 0.82

Low risk of recurrent thromboembolism in pregnancy. Br J Hosp Med (1987) 0.82

Osteopenia in pregnancy during long-term heparin treatment: a radiological study post partum. Br J Obstet Gynaecol (1990) 0.82

Epidemiology and natural history of venous thromboembolism. Prog Cardiovasc Dis (1994) 0.81

The percutaneous greenfield filter: outcomes and practice patterns. J Vasc Surg (2000) 0.80

Birth outcomes in pregnant women treated with low-molecular-weight heparin. Acta Obstet Gynecol Scand (2000) 0.80

Cost-effectiveness of prophylactic low molecular weight heparin in pregnant women with a prior history of venous thromboembolism. Am J Med (2005) 0.77

Heparin prophylaxis during pregnancy. Am J Obstet Gynecol (1990) 0.76

The Greenfield vena cava filter. Chest (1988) 0.76

Thromboprophylaxis during pregnancy. Am J Obstet Gynecol (1990) 0.76

Thromboembolism and its management in pregnancy. Med J Aust (1991) 0.76

Management of deep venous thrombosis and pulmonary embolism during pregnancy. Am J Surg (1982) 0.76